

80189\_Auto\_Edited.docx

5

**Name of Journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 80189

**Manuscript Type:** CASE REPORT

9

**Unusual breast metastasis of gastrointestinal stromal tumor: A case report and literature review**

8

## **INTRODUCTION**

Gastrointestinal stromal tumors (GISTs) are rare tumors, with an incidence 1%-2% and at the same time are the most frequent mesenchymal tumors of gastrointestinal tract<sup>[1]</sup>. Approximately 10% to 20% of patients present with metastatic disease<sup>[2]</sup>. Many evidences showed that gastrointestinal tumors can metastasize to other parts of the body<sup>[3]</sup>. The most common metastatic sites of GISTs are the liver (60%-70%) and the peritoneum (20%-30%)<sup>[4]</sup>. Lung metastases (2%-9%), bone and soft tissue (1%-6%) and skin (1%) can occur but very rare. Casuistic bizzare cases of GISTs metastasis to brain<sup>[5]</sup>, core<sup>[6]</sup>, ovary<sup>[7,8]</sup>, and breast<sup>[9]</sup> are described in the literature. We made a literature review, breast metastases from GIST have been previously described only in one case.

Breast tumors are usually primary. The incidence of metastatic spread from extramammary sites to the breast varies between 0.4% and 1.5% of all breast malignancies. The breast is considered to be resistant to metastasis because it contains large areas of fibrous tissue with a relatively low supply of blood. Most common malignancies that metastasize into the breast are lymphoma, leukemia, melanoma and carcinomas of stomach, ovary, lung, kidney and others<sup>[10-12]</sup>.

<sup>1</sup> In the article we report a second case of GIST patient presenting breast metastasis, highlighting the pathological/molecular features of this unusual site of metastatic presentation and the clinical implications.

## **CASE PRESENTATION**

*Chief complaints*

The 55-year-old female complained of the tumor in her right breast.

### *History of present illness*

In April 2016 55-year-old female patient presented with recurrent rectum tumor. Abdominal-perineal extirpation of rectum was performed, histology and immunohistochemistry study showed GIST, mixed type with CD117 and DOG-1 positive staining. After the surgery computer tomography (CT) revealed multiply cystic liver lesions that were estimated as metastases, biopsy was not done. At the same time, the patient found lesion in her right breast 30 mm, biopsy was not performed. The patient was taking imatinib 400 mg from June 2016 until August 2018 for 22 mo with stable disease.

In September 2018 Lesion in the right breast increased, liver lesions were stable and the dose of imatinib was doubled, the patient received imatinib 800mg from September until December 2018 with further growth of breast lesion. From December 2018 until March 2020 for 15 mo the patient was receiving sunitinib 50 mg 4/2 regiment. In March 2020 the dose of sunitinib was reduced to 25 mg every day without a break because of hand-food skin reaction grade 2 and then until February 2021 for 11 mo the patient continued the treatment with partial response lesion in the right breast and stable disease in the liver lesions. The toxicity of modified regiment was acceptable. The patient became hypothyroid and received levothyroxine 25 mcg.

In August 2020 breast ultrasound and magnetic resonance imaging were done at the first time and revealed heterogeneous lesion 47 mm on the border of the upper quadrants of the right breast with central zone of necrosis and peripheral vascularization, BIRADS 5 (Figure 1). The biopsy of the right breast was done to exclude primary breast cancer, histology and immunohistochemistry showed metastasis of GIST, mixed type, 10 mitoses with CD117 and DOG -1 positive staining.

In February 2021 <sup>10</sup> control positron emission tomography-computed tomography (PET-CT) in comparison with September 2020 was obtained and demonstrated progression in the right breast lesion, size increased from 39 mm to 48 mm and FDG

uptake increased from 7 to 12 and invasion to the large pectoral muscle was detected (Figure 2). The multiply liver metastases were stable.

### *History of past illness*

The patient had a rectum leiomyoma resection twice in 2012 and 2013 then the patient was on follow up until April 2016.

3

### *Personal and family history*

The patient's other medical history was not noteworthy.

### *Physical examination*

In the right breast on the border of the upper quadrants the solid lesion was revealed, 50 mm in size.

### *Laboratory examinations*

Laboratory testing showed any clinically significant abnormalities.

### *Imaging examinations*

In April 2021, histology and immunohistochemistry studies showed tumor macroscopical size 50 mm with thick fibrous capsule, with histologically negative margins (Figure 3); microscopic examination showed predominantly epithelioid type with focuses of spindle cell that occupied 15% of the square, with prominent hyperchromatic nuclei, high mitotic index (72 mitoses per 50 HPF), small foci of necrosis and large hemorrhagic areas; immunohistochemistry study showed immunophenotype typical for GIST: strong cytoplasmic expression CD34, membrane-cytoplasmic expression CD117 and DOG-1 (Figure 4).

### **MULTIDISCIPLINARY EXPERT CONSULTATION**

The clinical situation was estimated as local progression: increase of breast lesion and stable of the liver lesions. Because of growth of the breast metastasis the treatment was changed twice: the patient received double dose of imatinib and sunitinib. Taking into account that the patient had local progression we decided to remove increasing lesion.

### **FINAL DIAGNOSIS**

The final diagnosis was local progression: increase of breast lesion and stable of the liver lesions.

### **TREATMENT**

In April 2021 right breast resection with partial resection of large pectoral muscle was done. The patient had undergone surgery in 2012, 2013 and 2016 in different clinics, unfortunately histology materials were lost and we had no opportunity to compare histological specimens.

<sup>1</sup> Molecular analysis was performed on the breast metastasis by direct Sanger sequencing and revealed a KIT exon 11 mutation, with a consequent 557-559 deletion.

After surgery we decided to resume imatinib. Previously we changed treatment because of the growth of breast lesion (increased imatinib dose, prescribed sunitinib) and then we removed increased metastasis that is why we decided to return to less toxic treatment.

### **OUTCOME AND FOLLOW-UP**

From April 2021 until now patient has been taking imatinib for 19 mo without progression, PET-CT was done in November 2022. By November 2022 the live duration with metastatic GIST is 77 mo (Figure 5).

### **DISCUSSION**

We made a literature review, breast metastases from GIST have been previously described only in one case<sup>[9]</sup>. Hasbay *et al*<sup>[9]</sup> reported the clinical case of 46-year-old

women with metastases of GIST to liver, bone, abdominal lymph nodes and left breast. We reported the second case of GIST metastases to the breast.

In this case we came across with diagnostic challenges because <sup>1</sup>the most common metastatic sites of GIST are the liver and the peritoneum and at the same time metastasis to the breast from extramammary carcinomas is extremely rare and varies between 0.4% and 1.5% of all breast malignancies<sup>[10]</sup>. We usually deal with primary breast cancer because that is the most common female malignancies<sup>[13]</sup>.

<sup>2</sup>Recently, there is an increasing evidence regarding the association of sporadic GISTs with second neoplasia. <sup>2</sup>In a systematic review and meta-analysis conducted the rate of secondary tumors with GISTs was reported to be 20%<sup>[14]</sup>. Breast cancers are the most common malignancies together with GISTs.

Taking into account that breast metastasis from GISTs are extremely rare and that second tumors including breast cancer are common, at first in this clinical situation it is obligatory to exclude breast cancer that we have done.

Our patient had a local progression, growth only lesion in the breast, we removed increased metastasis that allowed us to return to less toxic treatment, the patient resumed imatinib. The critical question of whether surgery provides additional benefit over remaining on tyrosine kinase inhibitors (TKIs) therapy alone without surgical resection is unanswered. Randomized trials failed to recruit quickly enough to meet target accrual. In the absence of randomized trials, <sup>4</sup>single-institution and multi-institutional retrospective studies document long-term disease control and longer overall survival for selected patients who undergo metastasectomy of increased lesions while other lesions under control (local progression) on imatinib therapy. Removal of increased metastases let to continue imatinib therapy and not to change the TKIs that have less efficacy and not so favorable profile of toxicity. The median time to progression on sunitinib therapy is 6 mo, on regorafenib only 4 mo. Fairweather *et al*<sup>[15]</sup> published <sup>6</sup>the largest series of patients with metastatic GIST treated with TKI undergoing surgical resection ( $n = 323$ ). The median time to progression during imatinib therapy on local progression was 47 mo from the start of imatinib and 11 mo

from cytoreductive surgery, removal increasing lesions<sup>[15]</sup>. These data are consistent with the result of treatment of our patient; the duration of imatinib therapy after surgery is 19 mo that is more than four times higher than the median PFS on regorafenib therapy.

## **CONCLUSION**

In conclusion, breast metastases from GISTs are very rare, but it is clinically very important to distinguish primary from metastatic breast lesions.

## **REFERENCES**

- 1 **Miettinen M**, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001; **438**: 1-12 [PMID: 11213830 DOI: 10.1007/s004280000338]
- 2 **Miettinen M**, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. *Hum Pathol* 1999; **30**: 1213-1220 [PMID: 10534170 DOI: 10.1016/s0046-8177(99)90040-0]
- 3 **Tulsi R**, Ul Haque MM, Hanif FM, Devi A, Mubarak M, Hassan Luck N. Metastasis of Duodenal Adenocarcinoma to the Urinary Bladder Presenting as Hematuria. *J Transl Int Med* 2021; **9**: 143-145 [PMID: 34497753 DOI: 10.2478/jtim-2021-0010]
- 4 **Liu P**, Tan F, Liu H, Ge J, Liu S, Lei T, Zhao X. Skin Metastasis of Gastrointestinal Stromal Tumors: A Case Series and Literature Review. *Cancer Manag Res* 2020; **12**: 7681-7690 [PMID: 32904396 DOI: 10.2147/CMAR.S261823]
- 5 **Wong CS**, Chu YC. Intra-cranial metastasis of gastrointestinal stromal tumor. *Chin Med J (Engl)* 2011; **124**: 3595-3597 [PMID: 22340184 DOI: 10.3760/cma.j.issn.0366-6999.2011.21.029]
- 6 **Bashir U**, Qureshi A, Khan HA, Uddin N. Gastrointestinal stromal tumor with skeletal muscle, adrenal and cardiac metastases: an unusual occurrence. *Indian J Pathol Microbiol* 2011; **54**: 362-364 [PMID: 21623091 DOI: 10.4103/0377-4929.81638]

- 7 **De Leo A**, Nannini M, Dondi G, Santini D, Urbini M, Gruppioni E, De Iaco P, Perrone AM, Pantaleo MA. Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. *BMC Cancer* 2018; **18**: 301 [PMID: 29548310 DOI: 10.1186/s12885-018-4204-1]
- 8 **Irving JA**, Lerwill MF, Young RH. Gastrointestinal stromal tumors metastatic to the ovary: a report of five cases. *Am J Surg Pathol* 2005; **29**: 920-926 [PMID: 15958857 DOI: 10.1097/01.pas.0000155161.55915.c3]
- 9 **Hasbay B**, Aytaç HÖ, Kayaselçuk F, Torun N. An Unusual Gastrointestinal Stromal Tumor Presentain: Breast, Liver and Lymph Node Metastasis. *Eur J Breast Health* 2017; **13**: 216-218 [PMID: 29082381 DOI: 10.5152/ejbh.2017.3492]
- 10 **McFarlane ME**. Metastasis to the breast: a rare site for secondary malignancy. *Int J Surg* 2006; **4**: 204-205 [PMID: 17462351 DOI: 10.1016/j.ijssu.2005.10.008]
- 11 **Klingen TA**, Klaasen H, Aas H, Chen Y, Akslen LA. Secondary breast cancer: a 5-year population-based study with review of the literature. *APMIS* 2009; **117**: 762-767 [PMID: 19775345 DOI: 10.1111/j.1600-0463.2009.02529.x]
- 12 **Wang Y**, Hou K, Jin Y, Bao B, Tang S, Qi J, Yang Y, Che X, Liu Y, Hu X, Zheng C. Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways. *J Transl Int Med* 2021; **9**: 249-263 [PMID: 35136724 DOI: 10.2478/jtim-2021-0046]
- 13 **Siegel RL**, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. *CA Cancer J Clin* 2021; **71**: 7-33 [PMID: 33433946 DOI: 10.3322/caac.21654]
- 14 **Petrelli F**, Tomasello G, Barni S, Varricchio A, Costanzo A, Rampulla V, Cabiddu M, Turati L, Russo A, Seghezzi S, Passalacqua R, Ghidini M. Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. *Surg Oncol* 2019; **29**: 64-70 [PMID: 31196495 DOI: 10.1016/j.suronc.2019.03.001]
- 15 **Fairweather M**, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, Singer S, DeMatteo RP, Raut CP. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. *Ann Surg* 2018; **268**: 296-302 [PMID: 28448384 DOI: 10.1097/SLA.0000000000002281]



### **Figure Legends**

**Figure 1 Breast magnetic resonance imaging.** Heterogeneous lesion 47 mm (red arrows) on the border of the upper quadrants of the right breast with central zone of necrosis and peripheral vascularization. A: Axial; B: Frontal.

**Figure 2 Positron emission tomography-computed tomography.** A: Computed tomography (CT) on September 2020; B: CT on February 2021 demonstrated progression in the right breast lesion (red arrows), size increased from 39 mm to 48 mm.

**Figure 3 Macroscopic examination.** A, B: Macroscopical size 50 mm, thick fibrous capsule.

**Figure 4 Microscopic examination.** A: Histology, original magnification  $\times 200$ , hematoxylin-eosin stain; B: Immunohistochemistry original magnification  $\times 200$ , CD34 positive stain; C: Immunohistochemistry  $\times 200$ , CD117 positive stain, D: Immunohistochemistry original magnification  $\times 200$ , DOG-1 positive stain.

**Figure 5 Treatment timeline.**

14%

SIMILARITY INDEX

PRIMARY SOURCES

- 1 [bmccancer.biomedcentral.com](https://bmccancer.biomedcentral.com) 49 words — 3%  
Internet
- 2 Murat Koçer, Sadık Muallaoğlu, Bülent Çetin, Hasan Şenol Coşkun, Nermin Karahan, Osman Gürdal. "Second Primary Tumors in Patients with Gastrointestinal Stromal Tumors: A Single-Center Experience", Medicina, 2021 32 words — 2%  
Crossref
- 3 [www.wjgnet.com](http://www.wjgnet.com) 30 words — 2%  
Internet
- 4 "Gastrointestinal Stromal Tumors", Springer Science and Business Media LLC, 2017 17 words — 1%  
Crossref
- 5 [f6publishing.blob.core.windows.net](https://f6publishing.blob.core.windows.net) 16 words — 1%  
Internet
- 6 Mark Fairweather, Vinod P. Balachandran, George Z. Li, Monica M. Bertagnolli et al. "Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors", Annals of Surgery, 2018 15 words — 1%  
Crossref
- 7 Masahiro Yokouchi, Satoshi Nagano, Yuko Kijima, Takako Yoshioka, Akihide Tanimoto, Shoji Natsugoe, 11 words — 1%

8	<a href="http://www.mdpi.com">www.mdpi.com</a> Internet	11 words — 1%
9	<a href="http://wjgnet.com">wjgnet.com</a> Internet	10 words — 1%
10	<a href="http://www.researchgate.net">www.researchgate.net</a> Internet	10 words — 1%

EXCLUDE QUOTES ON  
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES < 1%  
EXCLUDE MATCHES < 10 WORDS